KROSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Keros Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026
$11.06+0.40 (+3.75%)
Close on Oct 19, 2026
- Market cap
- $218.99M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$2.77 (−20.03%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Keros Therapeutics, Inc. saw revenue fall 93.7% to $14.54M over the twelve months to Jun 30, 2026. Operating income fell 32621.8% to -$101.47M, moving the operating margin from 0.1% to -698.0%. Free cash flow was -$48.49M, down 191.3% from a year earlier.
Revenue
$14.54M
-93.7% vs. a year earlier
Operating income
-$101.47M
-32621.8% vs. a year earlier
Free cash flow
-$48.49M
-191.3% vs. a year earlier
EPS, diluted
-$3.68
-1287.1% vs. a year earlier
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $218.99M
- P/E ratio
- –
- Price to sales
- 15.07
- Price to book
- 0.83
- Dividend yield
- –
- Free cash flow yield
- -22.14%
Fundamentals
- Revenue
- $14.54M
- Net income
- -$83.16M
- EPS, diluted
- -$3.68
- Free cash flow
- -$48.49M
- Book value per share
- $13.25
- Diluted shares
- 20M
Eight years at a glance
Fiscal years 2018 to 2025 and trailing twelve months, USD
Revenue
$14.54M-93.7% YoY
Operating income
-$101.47M-32621.8% YoY
Net income
-$83.16M-543.0% YoY
EPS, diluted
-$3.68-1287.1% YoY
Free cash flow
-$48.49M-191.3% YoY
Reported periodTrailing twelve months